Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma. Hematol Oncol Stem Cell Ther 2011;4(1):1-9
Date
04/05/2011Pubmed ID
21460601DOI
10.5144/1658-3876.2011.1Scopus ID
2-s2.0-79956075049 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
High-dose chemotherapy followed by autologous hematopoietic cell transplantation continues to play an integral role in the treatment strategy in patients with newly diagnosed multiple myeloma. Incorporation of newer potent anti-myeloma agents has further improved outcomes. However, disease relapse or progression remains a challenge after autologous transplantation. Allogeneic hematopoietic cell transplantation remains the only potentially curative modality for some patients due in part to graft-versus-myeloma effect. High transplant-related mortality, in the range of 30% to 40%, previously seen with myeloablative conditioning regimens, including total body irradiation plus cyclophosphamide has been significantly reduced by introducing less ablative preparative regimens, so called reduced-intensity conditioning. Cumulative evidence suggests encouraging prospects for allogeneic transplantation through improved outcomes of myeloma patients (overall survival exceeding 70% at 2 years in some studies); however, which patient population would benefit most from this treatment remains to be defined. newer strategies to augment graft-versus-myeloma effect and minimize post transplant toxicities are in need of further improvement in patients with myeloma.
Author List
Nishihori T, Kharfan-Dabaja MA, Ochoa-Bayona JL, Bazarbachi A, Pasquini M, Alsina MAuthor
Marcelo C. Pasquini MD, MS Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Clinical Trials as TopicGraft vs Host Disease
Hematopoietic Stem Cell Transplantation
Humans
Multiple Myeloma
Transplantation Conditioning
Transplantation, Homologous
